Clinical studies show after 6 months of trying to conceive 75% of women have an ovulatory issue resulting in variable ovulation. OvuSense solves this problem by predicting ovulation 24 hours in advance using data from the current cycle which is not affected by this variability.

Fertility Focus Limited

115% INVESTMENT RAISED
Maturity

Sales and licensing

Sector Digital Health
Market

Fertility

Equity
Eligible for EIS
RISK WARNINGS – CAPITAL AT RISK
230000Funds Raised
200000Target
investors
Campaign finished

24 hour advance prediction of ovulation for all women including those with ovulatory issues
Diagnosis of ovulatory issues
Monitoring of fertility treatments
Previous Next
OvuSense - the only fertility monitor capable of 24 hour advance prediction, diagnosis and treatment monitoring
Fertility Focus Limited Warwick, UK and Old Saybrook, CT, USA
Visit Website Company LinkedIn Company Twitter Company Facebook

CE and FDA 510(k) approved as a medical device; with a portfolio of 9 patents; 5 clinical publications; and a proven business model, OvuSense™ is the only fertility monitor capable of:

  • 24 hour advance prediction of ovulation
  • 99% accurate detection of ovulation date
  • Diagnosis of ovulatory issues
  • Monitoring fertility treatment

The company was transformed in 2014 to sell OvuSense directly to the consumer via the company's dedicated ecommerce platform. An App version of the product was launched in 2016 and with over 3,500 customers in UK and USA.

With all technology, clinical and regulatory risks removed and the business model proven, the company is now seeking £1m growth capital to take the business to breakeven.

The team

The company has five full-time staff, supported by a non-exec board – a team with extensive experience in medtech and consumer businesses, and a history of successful exits. FF founded a 100% owned US Subsidiary in June 2015 and employs a part time COO to support the North American business hub.

Executive Team

Rob Milnes
CEO

Rob has over 26 years experience in financing and bringing ground-breaking medical technology and software to global markets, with the past 15 years focused on women’s health. He is also CEO of Fertility Focus Inc., the company’s wholly owned US subsidiary. Robert has worked for Roche, Oxford Instruments, and was formerly a member of the Operations Board of Huntleigh Healthcare following the successful sale and integration of the Sonicaid Fetal Monitoring and Medilog Cardiology businesses. He brings additional extensive experience in general management, sub-contract manufacturing, sales and marketing & M&A.

Key Team Members

Steve Godber
Chairman (non-executive)
Dr James Pardey
CTO
Laura Underwood
COO
Craig Citron
COO US Subsidiary